Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase I for Chronic Lymphocytic Leukemia...

Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for Multiple Myeloma (Kahler Disease): Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase I for Multiple Myeloma (Kahler...

Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Multiple Myeloma (Kahler Disease)

Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase I for B-Cell Acute Lymphocytic...

Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase III for Relapsed Acute Myeloid...

Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Relapsed Acute Myeloid Leukemia

Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase III for Refractory Acute Myeloid...

Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Refractory Acute Myeloid Leukemia

Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase I for Chronic Myelocytic Leukemia...

Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for Refractory Anemia With Ringed Sideroblasts: Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase II for Refractory Anemia With...

Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome. According...

Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for Leukemia: Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase II for Leukemia. According to...

Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for Myeloproliferative Disorders: Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase II for Myeloproliferative Disorders. According...

Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for Cytopenia: Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase II for Cytopenia. According to...

Data Insights

Iodine i 131 apamistamab by Actinium Pharmaceuticals for Refractory Anemia With Excess Blasts: Likelihood of Approval

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase II for Refractory Anemia With...